-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 12, the 2022 Fortune China 500 list was released
.
Kingfa Technology Co.
, Ltd.
ranks 311th on the list with an operating income of 40.
199 billion yuan in 2021
.
This is the 13th consecutive year that Kingfa Technology has been listed on the Fortune China 500 list, demonstrating its strong R&D strength, developed marketing network, efficient supply system, and high-quality products and services
.
The 2022 Fortune China 500 list, compiled by Fortune (Chinese version) in cooperation with CICC Fortune, considers the performance and achievements of the world's largest listed Chinese companies in the past year
.
Compared with the previous year's list, the revenue and net profit of the companies listed this year have increased significantly
.
According to the 2021 annual report of Kingfa Science and Technology, the entire group achieved operating income of 40.
199 billion yuan, a year-on-year increase of 14.
65%, and continued to deepen high-quality development
.
Among them: the sales volume of the modified plastics segment increased significantly, the product structure continued to be optimized, the share of major customers was further increased, and the sales volume of finished products was 1,745,300 tons; the new materials segment has an increasingly prominent position in the industry, and the operating quality has steadily improved.
The sales volume of finished products is 101,900 tons, a year-on-year An increase of 29.
32%; the construction of major projects in the green petrochemical sector is steadily progressing, and the scale competitiveness will be more obvious in the future; the production line of the medical and health sector is optimized and upgraded, and the brand influence continues to expand
.